Enanta Pharmaceuticals (ENTA)

Enanta’s pipeline is centred on oral therapies for diseases where targeted small molecules may offer convenient treatment options. In virology, its research and clinical programmes have focused on respiratory syncytial virus, SARS-CoV-2, hepatitis B virus, and other viral targets. RSV is a particularly important area because it causes significant illness in infants, older adults, and people with weakened immune systems, yet treatment options remain limited. Enanta has also worked on coronavirus antivirals designed to inhibit viral replication.

In immunology, the company is developing selective oral inhibitors aimed at inflammatory conditions, including diseases associated with type 2 immune responses. This reflects a broader strategy of using its chemistry platform beyond traditional antiviral research and into chronic immune-mediated disorders.

Enanta has historically generated a substantial portion of its revenue from royalties connected to hepatitis C products marketed by AbbVie, including therapies that incorporate Enanta-discovered protease inhibitor technology. As those royalty streams evolve, the company’s value increasingly depends on the progress of its internal clinical pipeline, regulatory outcomes, patent protection, and the competitive landscape for antivirals and immunology treatments.

As a biotech stock, ENTA represents exposure to drug discovery risk and potential clinical upside rather than a diversified commercial pharmaceutical business.